Showing results (61-70 of 102) with videos related to
Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, John Kuhn, H Ian Robins, et al.American Journal of Clinical Oncology|May 22, 2012
ACR Appropriateness Criteria® follow-up and retreatment of brain metastasesSamir H Patel, Jared R Robbins, Elizabeth M Gore, et al.Neuro-Oncology|June 19, 2008
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor ConsortiumSusan M Chang, Kathleen R Lamborn, John G Kuhn, et al.Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.Neuro-Oncology|August 15, 2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsElizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, et al.Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: single brain metastasisJohn H Suh, Gregory M M Videtic, Amr M Aref, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with afliberceptJohn F de Groot, Yuji Piao, Hai Tran, et al.Neurosurgery|April 5, 2018
Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported OutcomesWilliam A Hall, Stephanie L Pugh, Jeffrey S Wefel, et al.Neuro-Oncology|February 11, 2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados, W K A Yung, Kurt A Jaeckle, et al.Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.Pageof 11